发明申请
US20100234376A1 [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors
失效
[4,5']联吡啶基-6,4'-二胺衍生物作为蛋白激酶抑制剂
![[4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors](/docs/US/2010-09-16/US20100234376A1/abs.jpg.600x600.jpg)
- 专利标题： [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors
- 专利标题（中）： [4,5']联吡啶基-6,4'-二胺衍生物作为蛋白激酶抑制剂
-
申请号： US12373441申请日： 2007-07-10
-
公开(公告)号： US20100234376A1公开(公告)日： 2010-09-16
- 发明人: Pamela A. Albaugh , Yun He , Songchun Jiang , Pingda Ren , Xia Wang , Xing Wang , Yongping Xie
- 申请人： Pamela A. Albaugh , Yun He , Songchun Jiang , Pingda Ren , Xia Wang , Xing Wang , Yongping Xie
- 专利权人： Novartis AG
- 当前专利权人： Novartis AG
- 国际申请： PCT/US07/73111 WO 20070710
- 主分类号： A61K31/5377
- IPC分类号： A61K31/5377 ; C07D413/14 ; C07D403/04 ; A61K31/506 ; A61K31/497 ; A61P35/00
![[4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors](/abs-image/US/2010/09/16/US20100234376A1/abs.jpg.150x150.jpg)
摘要：
The invention provides a novel class of compounds of the Formula I: in which the symbols have the meanings given in the description and claims, to pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of FGFR3 kinase.
公开/授权文献
信息查询
IPC分类:
